7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Background: Erlotinib and gefitinib are epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs). They have the same mechanism of action and very similar side …

Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …

Introduction Inhibition of the epidermal growth factor receptor is a promising therapy in the
treatment of non-small cell lung cancer (NSCLC). In this systematic review, we evaluated the …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

BACKGROUND The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs), became an attractive therapeutic option for advanced non-small-cell lung cancer …

Tyrosine kinase inhibitors of the epidermal growth factor receptor, gefitinib and erlotinib,
have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) …